CoChat

Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited

Lachin, John M., Genuth, Saul, Nathan, David M., Zinman, Bernard, Rutledge, Brandy N., for the DCCT/EDIC Research Group · 2008 · Diabetes

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

OBJECTIVE— The Diabetes Control and Complications Trial (Diabetes 44:968–983, 1995) presented statistical models suggesting that subjects with similar A1C levels had a higher risk of retinopathy progression in the conventional treatment group than in the intensive treatment group. That analysis has been cited to support the hypothesis that specific patterns of glucose variation, in particular postprandial hyperglycemia, contribute uniquely to an increased risk of microvascular complications above and beyond that explained by the A1C level. RESEARCH DESIGN AND METHODS— We performed statistical evaluations of these models and additional analyses to assess whether the original analyses were flawed. RESULTS— Statistically, we show that the original results are an artifact of the assumptions of the statistical model used. Additional analyses show that virtually all (96%) of the beneficial effect of intensive versus conventional therapy on progression of retinopathy is explained by the reductions in the mean A1C levels, similarly for other outcomes. Furthermore, subjects within the intensive and conventional treatment groups with similar A1C levels over time have similar risks of retinopathy progression, especially after adjusting for factors in which they differ. CONCLUSIONS— A1C explains virtually all of the difference in risk of complications between the intensive and conventional groups, and a given A1C level has similar effects within the two treatment groups. While other components of hyperglycemia, such as glucose variation, may contribute to the risk of complications, such factors can only explain a small part of the differences in risk between intensive and conventional therapy over time.

Overview

Integrity signals

Registry

Crossref · 10.2337/db07-1618

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 13 references

Cited by

See all 555

Metadata

Authors
Lachin, J. M., Genuth, S., Nathan, D. M., Zinman, B., Rutledge, B. N., & for the DCCT/EDIC Research Group
Affiliations
  • George Washington University (US)
  • Case Western Reserve University (US)
  • Harvard University (US)
  • Mount Sinai Hospital (CA)
Venue
Diabetes
Published
2008-04-01
Volume
57
Issue
4
Pages
995-1001
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W1992103610
Cited by
555
References
13
Citations by year
2026: 21 · 2025: 41 · 2024: 31 · 2023: 31 · 2022: 34 · 2021: 28 · 2020: 31 · 2019: 26 · 2018: 31 · 2017: 31 · 2016: 30 · 2015: 31 · 2014: 36 · 2013: 36 · 2012: 25
FWCI
22.00
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Heart, Lung, and Blood Institute
  • National Eye Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • NIH Clinical Center
  • Division of Diabetes, Endocrinology, and Metabolic Diseases
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
glycemic exposure, glycemic variability, postprandial hyperglycemia, microvascular complications, diabetic retinopathy progression, HbA1c, tight glycemic control, Diabetes Control and Complications Trial
MeSH terms
Adolescent, Adult, Diabetes Mellitus, Type 1, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Insulin, Male, Reproducibility of Results, Models, Statistical, Cohort Studies, Biomarkers, Disease Progression, Patient Selection, Racial Groups

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.